Oncolys BioPharma Inc. (4588.T)
JPY 602.0
(-1.79%)
JPY 602.0
(-1.79%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.33 Billion | -1.71 Billion | -1.74 Billion | -1.46 Billion | -238.22 Million | -1.18 Billion |
| Net Income | -1.93 Billion | -1.14 Billion | -1.61 Billion | -2.09 Billion | -908.59 Million | -1.23 Billion |
| Depreciation & Amortization | 2.28 Million | 914 Thousand | 6.48 Million | 4.89 Million | 3.1 Million | 1.7 Million |
| Deferred income taxes | 156.32 Million | - | 61.68 Million | 377.39 Million | 364.05 Million | - |
| Stock-based compensation | 9.43 Million | 58.13 Million | 208.95 Million | 376.6 Million | 125.92 Million | - |
| Change in working capital | 552.41 Million | -501.78 Million | -532.58 Million | -129.75 Million | 148.73 Million | 37.03 Million |
| Other non-cash items | -118.87 Million | -128.39 Million | 125.35 Million | -2.98 Million | 28.53 Million | 3.78 Million |
| Investing Cash Flow | -5.39 Million | 20.11 Million | -942 Thousand | -37.57 Million | -4.44 Million | 342.04 Million |
| Investments in PPE | -5.68 Million | -1.35 Million | -1.43 Million | -2.7 Million | -4.29 Million | -1.64 Million |
| Acquisitions | 136 Thousand | - | - | -10.76 Million | - | - |
| Investment purchases | -1000.00 | -1000.00 | -1000.00 | -6000.00 | -6000.00 | -356.31 Million |
| Sales/Maturities of investments | - | - | 486 Thousand | -21.76 Million | - | 700 Million |
| Other Investing Activities | 159 Thousand | 21.47 Million | 10 Thousand | -2.34 Million | -146 Thousand | -1000.00 |
| Financing Cash Flow | 1.14 Billion | -113.83 Million | 3.09 Billion | 242.26 Million | 1.12 Billion | 1.14 Billion |
| Debt repayment | -98.98 Million | -111.1 Million | -122.23 Million | -100 Million | -77.78 Million | -43.33 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -28 Thousand | -36 Thousand | -95 Thousand | - | - |
| Common Stock Issuance | 1.24 Billion | - | 3.08 Billion | 245.5 Million | 1 Billion | 1.18 Billion |
| Other Financing Activities | 18.07 Million | -2.69 Million | 225.61 Million | 193.7 Million | 194.2 Million | 2.27 Million |
| Accounts receivables | 151.42 Million | 98.07 Million | -208.63 Million | 1.86 Million | -118.92 Million | 38.35 Million |
| Accounts payables | - | -98.07 Million | 208.63 Million | -1.86 Million | 118.92 Million | - |
| Inventory | 18.9 Million | -12.59 Million | -1.18 Million | 4.44 Million | -3.85 Million | 7.51 Million |
| Other working capital | 382.08 Million | -489.18 Million | -531.4 Million | -134.19 Million | 152.58 Million | 29.51 Million |
| Cash at beginning of period | 1.46 Billion | 3.2 Billion | 1.82 Billion | 3.09 Billion | 2.21 Billion | 1.92 Billion |
| Cash at end of period | 1.28 Billion | 1.46 Billion | 3.2 Billion | 1.82 Billion | 3.09 Billion | 2.21 Billion |
| Capital Expenditure | -5.68 Million | -1.35 Million | -1.43 Million | -2.7 Million | -4.29 Million | -1.64 Million |
| Effect of forex changes on cash | 21.33 Million | 67.41 Million | 38.17 Million | -14.14 Million | -1.2 Million | -6.11 Million |
| Net cash flow / Change in cash | -178.43 Million | -1.74 Billion | 1.38 Billion | -1.27 Billion | 879.44 Million | 295.62 Million |
| Free Cash Flow | -1.34 Billion | -1.71 Billion | -1.74 Billion | -1.46 Billion | -242.51 Million | -1.18 Billion |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -364.23 Million | -665.66 Million | -1.93 Billion | -404.08 Million | -545.07 Million | -323.69 Million |
| Depreciation & Amortization | - | 1.6 Million | 2.28 Million | 539 Thousand | 141 Thousand | - |
| Deferred income taxes | - | - | 156.32 Million | - | - | - |
| Stock-based compensation | - | 9.43 Million | 9.43 Million | -5.29 Million | 5.92 Million | - |
| Change in working capital | - | - | 552.41 Million | - | - | - |
| Other non-cash items | 364.23 Million | 656.22 Million | -118.87 Million | 409.37 Million | 539.14 Million | 323.69 Million |
| Investing Cash Flow | - | - | -5.39 Million | - | - | - |
| Investments in PPE | - | - | -5.68 Million | - | - | - |
| Acquisitions | - | - | 136 Thousand | - | - | - |
| Investment purchases | - | - | -1000.00 | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 159 Thousand | - | - | - |
| Financing Cash Flow | - | - | 1.14 Billion | - | - | - |
| Debt repayment | - | - | -98.98 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 1.24 Billion | - | - | - |
| Other Financing Activities | - | - | 18.07 Million | - | - | - |
| Accounts receivables | - | - | 151.42 Million | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 18.9 Million | - | - | - |
| Other working capital | - | - | 382.08 Million | - | - | - |
| Cash at beginning of period | - | 1.2 Billion | 1.46 Billion | 1.09 Billion | 1.4 Billion | 1.46 Billion |
| Cash at end of period | - | 1.53 Billion | 1.28 Billion | 1.2 Billion | 1.09 Billion | 1.4 Billion |
| Capital Expenditure | - | - | -5.68 Million | - | - | - |
| Effect of forex changes on cash | - | - | 21.33 Million | - | - | - |
| Net cash flow / Change in cash | - | 324.69 Million | -178.43 Million | 117.81 Million | -318.44 Million | -57.41 Million |
| Free Cash Flow | - | 3.21 Million | -1.34 Billion | 1.07 Million | 6.2 Million | - |
MGX
9405
IVCGF
SHUR
BOL
HTNGF